RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
You may also be interested in...
Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.
Reckitt Benckiser's new CEO Laxman Narasimhan has unveiled a turnaround plan which will see the company's OTC drugs and dietary supplements housed in a separate business to its infant nutrition products. RB is investing £2bn to get back on track after a couple of difficult years.
A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.